Rob Scott Selected Research

Cardiovascular Diseases (Cardiovascular Disease)

1/2018	Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
8/2017	Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
4/2015	Cardiovascular drug development: is it dead or just hibernating?
1/2015	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
1/2015	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
4/2014	Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.
4/2014	Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy.
11/2013	Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rob Scott Research Topics

Disease

8	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 11/2013
6	Hypercholesterolemia 06/2014 - 01/2014
3	Myalgia 06/2016 - 12/2012
3	Coronary Disease (Coronary Heart Disease) 04/2016 - 11/2014
3	Dyslipidemias (Dyslipidemia) 01/2016 - 04/2014
2	Atherosclerosis 11/2014 - 03/2008
2	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 11/2013 - 11/2012
1	Insulin Resistance 01/2017
1	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 06/2016
1	Coinfection 01/2016
1	Hepatitis C 01/2016
1	Nasopharyngitis 01/2015
1	Arthralgia (Joint Pain) 05/2014
1	Headache (Headaches) 05/2014
1	Back Pain (Backache) 05/2014
1	Pain (Aches) 05/2014
1	Spasm (Spasms) 05/2014
1	Hyperlipidemias (Hyperlipidemia) 05/2014
1	Myositis (Idiopathic Inflammatory Myopathies) 03/2014
1	Rhabdomyolysis 03/2014
1	Muscular Diseases (Myopathy) 03/2014
1	Homozygous Familial Hypercholesterolemia 11/2013
1	Inflammation (Inflammations) 01/2009
1	Retinal Detachment (Retinal Detachments) 01/2009
1	Coronary Artery Disease (Coronary Atherosclerosis) 03/2008

Drug/Important Bio-Agent (IBA)

12	oxidized low density lipoproteinIBA 01/2018 - 11/2012
11	evolocumabIBA 06/2016 - 11/2012
7	Ezetimibe (Zetia)FDA Link 06/2016 - 11/2012
7	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 06/2016 - 11/2012
7	LDL CholesterolIBA 01/2016 - 11/2012
3	LDL Lipoproteins (beta Lipoproteins)IBA 01/2018 - 11/2013
3	Monoclonal AntibodiesIBA 06/2016 - 11/2012
3	CholesterolIBA 03/2016 - 05/2014
2	Apoprotein(a) (Apolipoprotein (a))IBA 01/2018 - 04/2014
2	Cardiovascular AgentsIBA 08/2017 - 04/2015
2	Apolipoproteins E (ApoE)IBA 01/2017 - 11/2014
2	Proprotein Convertase 9IBA 06/2016 - 11/2012
2	Atorvastatin (Lipitor)FDA Link 04/2016 - 03/2016
2	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 01/2016 - 11/2013
2	SubtilisinIBA 01/2016 - 11/2013
1	Apolipoproteins AIBA 01/2018
1	Lipoprotein(a)IBA 01/2018
1	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2017
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	Cholesterol Esters (Cholesteryl Esters)IBA 01/2017
1	Creatine Kinase (Creatine Phosphokinase)IBA 03/2016
1	LipidsIBA 01/2016
1	PlasminogenIBA 04/2014
1	Glycoproteins (Glycoprotein)IBA 04/2014
1	LDL Receptors (LDL Receptor)IBA 11/2013
1	Serine Proteases (Serine Protease)IBA 11/2012
1	MiragelIBA 01/2009
1	AntioxidantsIBA 03/2008
1	succinobucol (AGI 1067)IBA 03/2008

Therapy/Procedure

8	Therapeutics 08/2017 - 11/2012
1	Drug Therapy (Chemotherapy) 11/2013
1	Percutaneous Coronary Intervention 03/2008